Our recent study has demonstrated that YKL-39 is expressed in human breast cancer, and its expression level were indicative of metastatic spread in patients who underwent neoadjuvant chemotherapy, as discussed below. This evidence concerns the gene CHI3L2 and breast carcinoma.